{
  "study_id": "NCT05351541",
  "agent": "framework",
  "run": 2,
  "p_primary_hypothesis_supported": 0.8,
  "effect_direction": "favours intervention",
  "effect_size_90pct_interval": {"low": 3, "high": 20, "metric": "Mean change in BPI interference, 0-70 scale, baseline to 1 month (positive = reduction)"},
  "moderator_prediction": "Psilocybin + placebo and psilocybin + modafinil arms reduce interference more than zolpidem-containing arms: zolpidem sedates and blunts attention and encoding, lowering the impact term of the session's mana pricing, while modafinil preserves attention.",
  "claim_ids_used": ["PM-0401", "PM-0369", "PM-0092", "PM-0110", "PM-0090", "PM-0107", "PM-1286", "PM-0485", "PM-0159", "PM-0104", "PM-0988"],
  "rationale": "The primary test is an uncontrolled within-subject change: every participant gets psilocybin in a supportive therapeutic setting with preparation and integration. The framework treats psilocybin as a chemical backdoor that relaxes high-level priors, delivered as a high-impact session whose intensity outweighs duration, in a setting that is itself causal. Pain interference is a self-rated, render-layer outcome where belief acts most, and the Prover reads ambiguous bodily signals as improvement. Add expectancy and regression to the mean in treatment-refractory recruits, and a significant pooled reduction at 1 month is likely despite n~30. Risks: small sample, low-dose participants, reporting that focuses on arm contrasts, and recency-driven fade by 1 month."
}